Short-term Revision of USP Chapter on Dissolution Testing
Recommendation

27-29 October 2026
Practical Approaches for Assessing the Risks of Impurities
On 29 December 2011, the USP announced that the appropriate experts group of the USP had revised General Chapter <711> - Dissolution Testing. This revision will enter into force on 1st February 2012.
The background for the revision is the removal of Chlorpheniramine Maleate Extended-Release Tablets RS from the list of reference standards and from the Apparatus Suitability section.
The standard used until now had turned out and couldn't be replaced.
The USP is currently in the process of identifying replacement materials to be used in the Performance Verification Test for Apparatus 3.
The revised Chapter will be integrated in the second supplement of USP 35 - NF 30.
Further information is available in the Revision Bulletin - General Chapter <711> Dissolution as well as in the revised chapter.
Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
19.10.2026EMA Updates Information Page on Bioequivalence Guidelines
19.10.2026BP Publishes new Draft Texts
19.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination
